跳至主要内容
临床试验/NCT00315718
NCT00315718已完成3 期

Controlled Clinical Trial on Long Term Effects of Hintonia Latiflora Extract in Mild to Moderate Type 2 Diabetes

Harras Pharma Curarina GmbH1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2002年6月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
HbA1c values

研究概览

简要总结

In patients with diabetes mellitus type 2 stably adjusted to diet long-term intake of aqueous-ethanolic extract from Hintonia latiflora over more than 12 months leads to a statstically significant amelioration of parameters of glycaemic control (HbA1c, postprandial and fasting glucose) not acchievable with diet alone.

As safety parameters, liver function tests and cardiovascular parameters are to be monitored. Adverse events are to be monitored.

详细描述

Objective:

To evaluate the long term effects of an aqueous-ethanolic extract from the bark of Hintonia latiflora (1:4.5, extraction medium 32% ethanol) in mild to moderate cases of type II diabetes, especially on parameters of glycaemic control and safety.

Research Design and Methods:

The trial was carried out as a controlled single-centre open study. 30 patients stably adjusted to diet were treated with the study medication (3 x 2 ml/day before meals) for up to 36 months. Efficacy parameters were HbA1c and fasting and postprandial serum glucose. As parameters for safety, liver function tests, cardiac functions and adverse events were assessed.

Results:

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Mild to moderate Diabetes mellitus type 2 stable adjusted to diet
  • •Minimum duration of diabetic complaints 1 year
  • •Fasting serum glucose 7-14 mmol/l
  • •HbA1c max. 12%
  • •Written consent

排除标准

  • •Hepatic impairment
  • •Renal impairment
  • •Pregnancy

结局指标

主要结局

HbA1c values

次要结局

  • General vegetative symptoms
  • Postprandial blood glucose
  • Fasting blood glucose
  • BMI
  • Liver function tests (ALT, GGT, AP)
  • Serum lipids (triglycerides, cholesterol, HDL cholesterol)
  • Adverse drug reactions (narratives)
  • Blood pressure (systolic/diastolic)

研究者

发起方
Harras Pharma Curarina GmbH
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验